A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors.
Wei ZhangAurélie AugusteXiaoyun LiaoChristian WalterskirchenKathrin BauerYu-Hsi LinLing YangFarzaneh SayedianMarkus FabitsMichael M BergmannCarina BinderLeticia CorralesAnne B VogtLindsey J HudsonMartin P BarnesArnima BishtCraig GiragossianVladimir VoynovPaul J AdamSusanne HippPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
These data highlight the potential of the B7-H6/CD3 ITE to induce T cell-redirected lysis of tumor cells and recruitment of T cells into noninflamed tumor tissues, leading to antitumor activity in in vitro, in vivo, and human tumor slice cultures, which supports further evaluation in a clinical study.